Inhibiting the Src/STAT3 signaling pathway contributes to the anti‑melanoma mechanisms of dioscin

  • Authors:
    • Yu‑Xi Liu
    • Bo‑Wen Xu
    • Ying‑Jie Chen
    • Xiu‑Qiong Fu
    • Pei‑Li Zhu
    • Jing‑Xuan Bai
    • Ji‑Yao Chou
    • Cheng‑Le Yin
    • Jun‑Kui Li
    • Ya‑Ping Wang
    • Jia‑Ying Wu
    • Ying Wu
    • Kam‑Kwan Chan
    • Chun Liang
    • Zhi‑Ling Yu
  • View Affiliations

  • Published online on: January 17, 2020     https://doi.org/10.3892/ol.2020.11315
  • Pages: 2508-2514
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Late stage melanoma is associated with a high mortality rate. Signal transducer and activator of transcription 3 (STAT3) is currently a target for melanoma treatment as it is constitutively activated with high frequency in melanoma. Dioscin is a natural steroid saponin that is present in several medical herbs. A previous study demonstrated that dioscin inhibits STAT3 signaling in a cerebral ischemia‑reperfusion injury rat model. Furthermore, dioscin has been reported to exert anti‑melanoma effects in B16 melanoma cells and a B16 allograft mouse model. The present study investigated whether inhibition of STAT3 signaling is involved in the anti‑melanoma effects of dioscin. The results of the present study demonstrated that dioscin significantly decreased viability, induced apoptosis and suppressed migration of human A375 melanoma cells and murine B16F10 melanoma cells. Furthermore, dioscin inhibited the phosphorylation of STAT3 and Src (an upstream kinase of STAT3), and downregulated mRNA levels of STAT3‑targeted genes, including B‑cell lymphoma‑2, cyclin D1 and matrix metalloproteinase‑2. In addition, overexpression of STAT3 decreased the anti‑proliferative effects of dioscin. Overall, the results of the present study indicate that inhibiting the Src/STAT3 signaling pathway contributes to the anti‑­melanoma molecular mechanisms of dioscin. These results provide further pharmacological groundwork for developing dioscin as a novel anti‑melanoma agent.
View Figures
View References

Related Articles

Journal Cover

March-2020
Volume 19 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Liu, Y., Xu, B., Chen, Y., Fu, X., Zhu, P., Bai, J. ... Yu, Z. (2020). Inhibiting the Src/STAT3 signaling pathway contributes to the anti‑melanoma mechanisms of dioscin. Oncology Letters, 19, 2508-2514. https://doi.org/10.3892/ol.2020.11315
MLA
Liu, Y., Xu, B., Chen, Y., Fu, X., Zhu, P., Bai, J., Chou, J., Yin, C., Li, J., Wang, Y., Wu, J., Wu, Y., Chan, K., Liang, C., Yu, Z."Inhibiting the Src/STAT3 signaling pathway contributes to the anti‑melanoma mechanisms of dioscin". Oncology Letters 19.3 (2020): 2508-2514.
Chicago
Liu, Y., Xu, B., Chen, Y., Fu, X., Zhu, P., Bai, J., Chou, J., Yin, C., Li, J., Wang, Y., Wu, J., Wu, Y., Chan, K., Liang, C., Yu, Z."Inhibiting the Src/STAT3 signaling pathway contributes to the anti‑melanoma mechanisms of dioscin". Oncology Letters 19, no. 3 (2020): 2508-2514. https://doi.org/10.3892/ol.2020.11315